Phio Receives U.S. Notice of Allowance for PH-894 Patent
Phio Pharmaceuticals received a U.S. Notice of Allowance for a patent covering PH-894, strengthening protection for its INTASYL® platform and intellectual property portfolio. The company says the patent milestone supports advancing PH-894 in the U.S. and pursuing international strategic collaborations, while INTASYL compounds are designed to enhance immune cells to kill cancer cells.